Skip to content
Screener

Johnson & Johnson JNJ EPS (Diluted)

EPS (Diluted) at other companies

Abbott logo
AbbottABT
$0.53-47.5%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.62+153%
Tenet Healthcare logo
Tenet HealthcareTHC
$9.84+213%
Pfizer logo
PfizerPFE
-$0.04-108%
Procter & Gamble logo
Procter & GamblePG
$6.62+347%
Merck & Co. logo
Merck & Co.MRK
-$0.54-131%

Other financials

Income statement

See full
Revenue$25.3B+6.6%
Gross profit$17.3B+7.1%
Operating income$7.1B+7.4%
Net income$5.5B-0.1%

Balance sheet

See full
Cash & equivalents$20.4B+9.9%
Total debt$49.0B-3.4%
Total equity$85.0B+8.3%
Total assets$201.06B+4.0%

Cash flow

See full
Operating cash flow$8.6B+122%
CapEx$1.3B+26.7%
Free cash flow$7.3B+157%

Valuation

See full
Market cap$650.67B+52.8%
Enterprise value$679.29B+48.3%
P/E30.9×+12.1×
P/S6.6×+1.9×

Profitability

See full
Gross margin67.9%0.0pp
Operating margin26.5%+2.8pp
Net margin21.5%-3.5pp
FCF margin22.7%+2.2pp

Returns & leverage

See full
Return on equity25.7%-4.5pp
Debt / equity0.6×-0.1×
Current ratio1.1×+0.1×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Johnson & Johnson’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000200406-26-000153
Line itemFiscal Second Quarter Ended / June 28,2026Fiscal Second Quarter Ended / Percentto SalesFiscal Second Quarter Ended / June 29,2025Fiscal Second Quarter Ended / Percentto Sales
Provision for taxes on income (Note 5)1,2134.89544.0
Net earnings$5,53421.9%$5,53723.3%
Net earnings per share (Note 8)
Basic$2.30$2.30
Diluted$2.27$2.29
Avg. shares outstanding
Basic2,407.42,406.3
Diluted2,440.12,419.1

Item 1 — Financial statements

FAQ

What is Johnson & Johnson's EPS (diluted)?
Johnson & Johnson (JNJ) reported EPS (diluted) of $2.27 in Q2 2026.
How has Johnson & Johnson's EPS (diluted) changed year-over-year?
Johnson & Johnson's EPS (diluted) decreased by 0.9% year-over-year, from $2.29 to $2.27.
What is the long-term trend for Johnson & Johnson's EPS (diluted)?
Over 4 years (2021 to 2025), Johnson & Johnson's EPS (diluted) has grown at a 9.0% compound annual growth rate (CAGR), from $7.81 to $11.04.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Johnson & Johnson's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude